SUMMARY OF CHANGES Update: April 3, 2008
RTOG 0622, A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy

Study Chair Richard K. Valicenti, MD, MA; (215) 955-5936; richard.valicenti@mail.tju.edu

---

RTOG 0622 has been updated as follows:

Title page: Study chair contact information format was made consistent with RTOG standard.

Section 5.2.2: Note regarding preregistration study agent requirements for international sites was added to meet RTOG standard.

Section 7.4: Note regarding preregistration study agent requirements for international sites was added to meet RTOG standard.

Appendix II: Footnote was removed as no longer RTOG standard; adverse event reporting is already covered in Sections 11.2-3.

Note: These are editorial/administrative changes to the protocol. NCI requires that these changes be documented on the protocol title page as "Update Date."